Adding Winrevair to standard pulmonary arterial hypertension (PAH) treatment is generally safe and effective, a pooled trial ...

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.

We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

Merck‘s performance in 2025 started rough due to weaker-than-expected results, despite surpassing Wall Street estimates with ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Merck & Co., Inc. (MRK) is facing short-term challenges but remains a strong player in the healthcare sector. Over the last six months, the company’s stock has dropped nearly 27% due to ...

Merck Research Laboratories stated, “based on the strong, positive interim efficacy data from the ZENITH trial, as well as the totality of available Winrevair data, we concluded that it would not be ...

Annual Keytruda sales already exceed $31 billion, so Merck will need at least a few more Winrevair-sized drug launches to offset the upcoming losses. Behind Winrevair, though, there isn't much in ...